Xevinapant
Xevinapant is a small molecule pharmaceutical. It is currently being investigated in clinical studies.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
No data
Clinical
Clinical Trials
18 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Squamous cell carcinoma of head and neck | D000077195 | — | — | 1 | 2 | 2 | — | 1 | 6 |
| Carcinoma | D002277 | — | C80.0 | 1 | 2 | 1 | — | 1 | 5 |
| Squamous cell carcinoma | D002294 | — | — | 1 | 2 | 1 | — | 1 | 5 |
| Head and neck neoplasms | D006258 | — | — | 2 | 1 | 1 | — | — | 4 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neoplasms | D009369 | — | C80 | 4 | 1 | — | — | — | 4 |
| Mouth neoplasms | D009062 | EFO_0003868 | C06.9 | — | 1 | — | — | — | 1 |
| Oropharyngeal neoplasms | D009959 | — | — | — | 1 | — | — | — | 1 |
| Lip neoplasms | D008048 | — | C00 | — | 1 | — | — | — | 1 |
| Laryngeal neoplasms | D007822 | EFO_0003817 | C32 | — | 1 | — | — | — | 1 |
| Hypopharyngeal neoplasms | D007012 | — | C13 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 2 | — | — | — | — | 2 |
| Non-small-cell lung carcinoma | D002289 | — | — | 1 | — | — | — | — | 1 |
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 1 | — | — | — | — | 1 |
| Adenocarcinoma | D000230 | — | — | 1 | — | — | — | — | 1 |
| Leukemia | D007938 | — | C95 | 1 | — | — | — | — | 1 |
| Myeloid leukemia acute | D015470 | — | C92.0 | 1 | — | — | — | — | 1 |
| Myeloid leukemia | D007951 | — | C92 | 1 | — | — | — | — | 1 |
| Lymphoma | D008223 | — | C85.9 | 1 | — | — | — | — | 1 |
| Recurrence | D012008 | — | — | 1 | — | — | — | — | 1 |
| Glioma | D005910 | EFO_0000520 | — | 1 | — | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Xevinapant |
| INN | xevinapant |
| Description | At-406 is a small molecule pharmaceutical. It is currently being investigated in clinical studies. The pharmaceutical is active against tyrosine-protein kinase SYK, tyrosine-protein kinase Lyn, and tyrosine-protein kinase ABL1. In addition, it is known to target proto-oncogene tyrosine-protein kinase receptor Ret. |
| Classification | Small molecule |
| Drug class | inhibitor of apoptosis protein (IAP); vinca alkaloids |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CN[C@@H](C)C(=O)N[C@H]1CN(C(=O)CC(C)C)CC[C@H]2CC[C@@H](C(=O)NC(c3ccccc3)c3ccccc3)N2C1=O |
Identifiers
| PDB | — |
| CAS-ID | 1071992-57-8 |
| RxCUI | — |
| ChEMBL ID | CHEMBL2158051 |
| ChEBI ID | — |
| PubChem CID | 25022340 |
| DrugBank | DB16305 |
| UNII ID | N65WC8PXDD (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
No data
Safety
Black-box Warning
No Black-box warning
Adverse Events
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use